ACAD vs. NTLA

Last updated Jun 4, 2026

ACAD (ACADIA Pharmaceuticals Inc.) and NTLA (Intellia Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, ACAD returned -5.07%/yr vs -7.63%/yr for NTLA. At a 0.42 correlation, their price movements are largely independent.

Performance

ACAD vs. NTLA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ACADIA Pharmaceuticals Inc. (ACAD) and Intellia Therapeutics, Inc. (NTLA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ACAD achieves a -19.77% return, which is significantly lower than NTLA's 44.83% return. Over the past 10 years, ACAD has outperformed NTLA with an annualized return of -5.07%, while NTLA has yielded a comparatively lower -7.63% annualized return.

ACAD

• 1D: 2.58%
• 1M: -3.42%
• YTD: -19.77%
• 6M: -17.19%
• 1Y: -2.50%
• 3Y*: -4.51%
• 5Y*: -1.99%
• 10Y*: -5.07%

NTLA

• 1D: -0.84%
• 1M: -6.13%
• YTD: 44.83%
• 6M: 43.71%
• 1Y: 69.31%
• 3Y*: -31.75%
• 5Y*: -29.01%
• 10Y*: -7.63%

*Multi-year figures are annualized to reflect compound growth (CAGR)

ACAD vs. NTLA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ACAD ACADIA Pharmaceuticals Inc.	-19.77%	45.56%	-41.39%	96.67%	-31.79%	-56.34%	24.96%	164.56%	-46.30%	4.40%
NTLA Intellia Therapeutics, Inc.	44.83%	-22.90%	-61.76%	-12.61%	-70.49%	117.35%	270.82%	7.47%	-28.98%	46.61%

Correlation

The correlation between ACAD and NTLA is 0.33, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.33
Correlation (3Y) Calculated over the trailing 3-year period	0.39
Correlation (5Y) Calculated over the trailing 5-year period	0.43
Correlation (10Y) Calculated over the trailing 10-year period	0.42
Correlation (All Time) Calculated using the full available price history since May 9, 2016	0.42

Fundamentals

Market Cap ACAD : $3.70B NTLA : $1.54B
EPS ACAD : $2.20 NTLA : -$3.58
PS Ratio ACAD : 3.34 NTLA : 21.71
PB Ratio ACAD : 2.97 NTLA : 2.48
Total Revenue (TTM) ACAD : $1.10B NTLA : $66.09M
Gross Profit (TTM) ACAD : $758.58M NTLA : -$33.92M
EBITDA (TTM) ACAD : $104.56M NTLA : -$299.32M

Return for Risk

ACAD vs. NTLA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ACAD

ACAD Risk / Return Rank: 36
ACAD Sharpe Ratio Rank: 38
ACAD Sortino Ratio Rank: 33
ACAD Omega Ratio Rank: 33
ACAD Calmar Ratio Rank: 38
ACAD Martin Ratio Rank: 37

NTLA

NTLA Risk / Return Rank: 63
NTLA Sharpe Ratio Rank: 64
NTLA Sortino Ratio Rank: 65
NTLA Omega Ratio Rank: 68
NTLA Calmar Ratio Rank: 61
NTLA Martin Ratio Rank: 56

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ACAD vs. NTLA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ACADIA Pharmaceuticals Inc. (ACAD) and Intellia Therapeutics, Inc. (NTLA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ACAD	NTLA	Difference
Sharpe ratio Return per unit of total volatility	-0.07	0.73	-0.80
Sortino ratio Return per unit of downside risk	0.17	1.51	-1.34
Omega ratio Gain probability vs. loss probability	1.02	1.22	-0.20
Calmar ratio Return relative to maximum drawdown	-0.09	0.98	-1.07
Martin ratio Return relative to average drawdown	-0.17	1.55	-1.72
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ACAD vs. NTLA - Sharpe Ratio Comparison

The current ACAD Sharpe Ratio is -0.07, which is lower than the NTLA Sharpe Ratio of 0.73. The chart below compares the historical Sharpe Ratios of ACAD and NTLA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	ACAD	NTLA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.07	0.73	-0.80
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.04	-0.36	+0.33
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.08	-0.10	+0.02
Sharpe Ratio (All Time) Calculated using the full available price history	0.06	-0.07	+0.13

Drawdowns

ACAD vs. NTLA - Drawdown Comparison

The maximum ACAD drawdown since its inception was -96.29%, roughly equal to the maximum NTLA drawdown of -96.45%. Use the drawdown chart below to compare losses from any high point for ACAD and NTLA.

Drawdown Indicators

	ACAD	NTLA	Difference
Max Drawdown Largest peak-to-trough decline	-96.29%	-96.45%	+0.16%
Max Drawdown (1Y) Largest decline over 1 year	-27.58%	-71.27%	+43.69%
Max Drawdown (3Y) Largest decline over 3 years	-57.87%	-86.36%	+28.49%
Max Drawdown (5Y) Largest decline over 5 years	-57.87%	-96.45%	+38.58%
Max Drawdown (10Y) Largest decline over 10 years	-77.18%	-96.45%	+19.27%
Current Drawdown Current decline from peak	-62.40%	-92.63%	+30.23%
Average Drawdown Average peak-to-trough decline	-50.15%	-57.04%	+6.89%
Ulcer Index Depth and duration of drawdowns from previous peaks	14.70%	44.93%	-30.23%

Volatility

ACAD vs. NTLA - Volatility Comparison

The current volatility for ACADIA Pharmaceuticals Inc. (ACAD) is 10.49%, while Intellia Therapeutics, Inc. (NTLA) has a volatility of 18.74%. This indicates that ACAD experiences smaller price fluctuations and is considered to be less risky than NTLA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ACAD	NTLA	Difference
Volatility (1M) Calculated over the trailing 1-month period	10.49%	18.74%	-8.25%
Volatility (6M) Calculated over the trailing 6-month period	26.13%	53.80%	-27.67%
Volatility (1Y) Calculated over the trailing 1-year period	36.89%	95.55%	-58.66%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	55.51%	80.62%	-25.11%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	62.09%	78.25%	-16.16%

Dividends

ACAD vs. NTLA - Dividend Comparison

Neither ACAD nor NTLA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both ACAD and NTLA in my portfolio?

ACAD and NTLA have a correlation of 0.33, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ACAD or NTLA?

NTLA has higher volatility (18.74%) compared to ACAD (10.49%). In terms of maximum drawdown, ACAD dropped -96.29% vs NTLA's -96.45%.

Which has better risk-adjusted returns?

NTLA currently has the higher Sharpe Ratio (0.73 vs -0.07), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.